Q32 Bio to release alopecia areata trial data on July 13

Q32 Bio Inc. (Nasdaq: QTTB) announced it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe alopecia areata on July 13, 2026.

The company will host a conference call and webcast at 8:00 a.m. ET on that date to discuss the results.

Bempikibart, also known as ADX-914, is a fully human anti-IL-7Rα antibody being evaluated for the treatment of alopecia areata. According to the National Alopecia Areata Foundation, approximately 700,000 people in the United States live with the condition.

You May Also Be Interested In

• Bessent: We Make A Market Buying Older Bonds
• Citi reiterates Buy rating on AMD with $575 price target post TMT conference
• Intel (INTC) call put ratio 2.5 calls to 1 put with a focus on October 2 weekly calls as share price up 7.8%